Arcutis Biotherapeutics
As of the edition of 20 October 2026, Arcutis Biotherapeutics runs 3 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Arcutis Biotherapeutics was renamed in 2019.
- ARCUTIS BIOTHERAPEUTICS INC: renamed in 2019
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Status not established | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Roflumilast | none listed | 4 |
A route B row is one company at one target.
Where its trials are
- Skin and connective tissue: 2 trials led
- Immune system: 1 trials led
- Inherited and neonatal: 1 trials led